WeTrials
Recruiting

First-in-Human Study of STX-478, a Mutant-Selective PI3Kα Inhibitor as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors

What is this study?

This clinical trial is testing a new experimental medicine called STX-478, both on its own and combined with other cancer drugs. The study aims to find the safest and most effective dose for treating advanced solid tumors and hormone receptor-positive breast cancer that have a specific genetic change.

Who can participate?

Adults aged 18 and older with advanced solid tumors or hormone receptor-positive breast cancer that has a specific PI3Kalpha genetic mutation may be able to join. Participants need to be well enough to handle daily activities and provide a recent tumor tissue sample.

What will happen?

Depending on the study part you join, you will receive the experimental drug STX-478 either by itself or combined with standard hormone therapies and other cancer-fighting medications. Your health team will carefully monitor you throughout the process, starting with a 28-day screening period.

Where and when?

This study is currently recruiting participants at multiple locations, including sites in Los Angeles and San Francisco, California, as well as Aurora, Colorado.

Key Points
  • 1Testing an experimental targeted cancer treatment called STX-478
  • 2Options include taking the study drug alone or combined with existing cancer therapies
  • 3Open to adults with advanced solid tumors and specific genetic mutations

No related links yet

Seen this study covered in the news, or found a page that explains it well? Send it over and we'll review it.

Suggest a link
Conditions Studied
This study is investigating treatments for the following conditions
Breast CancerSolid Tumors, Adult

This summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.